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Effects of Ramipril on
Endothelial Function and the Expression
of Proinflammatory Cytokines and Adhesion
Molecules in Young Normotensive Subjects
With Successfully Repaired Coarctation of Aorta
A Randomized Cross-Over Study
Stella Brili, MD, FACC, Dimitris Tousoulis, MD, PHD, FACC, Charalambos Antoniades, MD,
Carmen Vasiliadou, MSC, Maria Karali, MD, Nikos Papageorgiou, MD, Nikos Ioakeimidis, MD,
Kyriakoula Marinou, MD, Elli Stefanadi, MD, Christodoulos Stefanadis, MD, FACC, FESC
Athens, Greece
Objectives The purpose of this study was to evaluate the effect of ramipril on endothelial function and inflammatory pro-
cess in a group of normotensive subjects with successfully repaired coarctation of the aorta (SCR).
Background Subjects with SCR experience higher long-term cardiovascular risk as a result of the relapse of arterial hyperten-
sion or owing to nonreversible structural changes in the pre-coarctation arterial tree. These subjects experience
endothelial dysfunction in the right forearm and appear to have elevated levels of proatherogenic inflammatory
markers, even in the absence of arterial hypertension.
Methods Twenty young individuals age 27.3 2.4 years old with SCR 13.9  2.2 years previously, received ramipril 5 mg/day
for 4 weeks in a randomized, cross-over, controlled trial. Endothelial function was evaluated in the right forearm by
gauge-strain plethysmography, and serum levels of interleukin (IL)-1b, IL-6, soluble CD40 ligand (sCD40L), and solu-
ble vascular cell adhesion molecule (sVCAM)-1 were determined by enzyme-linked immunosorbent assay.
Results Ramipril improved endothelial function (p 0.001) and decreased the expression of proinflammatory cytokine IL-6
(p  0.05) and sCD40L (p  0.01). Furthermore, ramipril decreased serum levels of sVCAM-1 (p 0.01) but failed to
affect serum levels of C-reactive protein. These effects were independent of blood pressure lowering.
Conclusions Ramipril reversed the impaired endothelial function and decreased the expression of proinflammatory cyto-
kine IL-6, sCD40L, and adhesion molecules in normotensive subjects with SCR. These findings imply that
ramipril treatment may have antiatherogenic effects in subjects with SCR, even in the absence of arterial
hypertension. (J Am Coll Cardiol 2008;51:742–9) © 2008 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.10.036e
a
s
g
m
i
c
(
p
s
ct is now well documented that adults with successfully
epaired coarctation of the aorta (SCR) experience higher
isk for premature atherosclerosis than the general popula-
ion (1,2). Despite the early and successful surgical repair of
ortic coarctation, these subjects appear to have persisting
ascular abnormalities such as impaired endothelial function
3,4) and abnormal elastic properties of large vessels (4–6),
rom the First Cardiology Department, Athens University Medical School, Hip-
okration Hospital, Athens, Greece. Drs. Brili and Tousoulis contributed equally to
his study.o
Manuscript received August 6, 2007; revised manuscript received October 16,
007, accepted October 22, 2007.specially at the pre-coarctation arterial tree (3,4,7). In
ddition, these subjects appear to have higher levels of
everal proinflammatory molecules with a key role in athero-
enesis, such as proinflammatory cytokines and adhesion
olecules, as we have previously shown (4). Although the
ncreased cardiovascular risk identified in these patients
ould be the result of the commonly relapsed hypertension
at rest or during exercise) (1,8), it seems that the observed
roatherogenic abnormalities are also observed in the ab-
ence of arterial hypertension (4).
Recent studies have demonstrated that angiotensin-
onverting enzyme inhibitors (ACEI) have a number
f beneficial effects on vascular function in patients with
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February 19, 2008:742–9 Ramipril and Aortic Coarctationdvanced atherosclerosis or arterial hypertension, and
hey decrease cardiovascular risk (9). In addition to their
ntihypertensive effect, ACEI have anti-inflammatory
roperties, improve nitric oxide (NO) bioavailability in human
asculature, and modify cardiovascular risk by interfering
irectly into the mechanisms of atherogenesis (10). Al-
hough the use of ACEI is recommended for hypertensive
atients with SCR, their effects on endothelial function and
nflammatory process in subjects with SCR and normal
lood pressure are unknown.
In this randomized, cross-over, controlled study, we
ypothesized that treatment with the ACEI ramipril may
xert direct beneficial effects on vascular function in
ormotensive patients with SCR. We hypothesized that
amipril may improve endothelial function and decrease
he expression of proinflammatory cytokines and adhe-
ion molecules in a population of nonhypertensive low-
isk subjects with SCR.
ethods
tudy population. A total of 50 subjects with SCR (resec-
ion and end-to-end anastomosis in all) were initially
creened for eligibility. Twenty-three of them fulfilled the
nclusion criteria, and 20 agreed to participate. The patients
ere recruited from the registry of Hippokration Hospital
n Athens. The successful repair of aortic coarctation was
onfirmed by continuous Doppler gradient at the distending
orta 25 mm Hg, the presence of palpable femoral pulses,
nd no radiofemoral delay.
Exclusion criteria were the presence of resting hyper-
ension (140/90 mm Hg as evaluated by 3 subsequent
office” blood pressure measurements and 24-h blood
ressure monitoring) (11). Additional exclusion criteria
ere the presence of exercise-induced arterial hyperten-
ion, left ventricular hypertrophy, overt atherosclerotic
eripheral vascular disease, presence of any acute or
hronic inflammatory diseases (e.g., liver diseases), or any
ther cardiac disease (including coronary artery disease
ocumented by medical history and exercise stress test).
ubjects with any classic risk factor for atherosclerosis or
eceiving any systemic medication were also excluded
rom the study. In particular, we excluded patients with
stablished risk factors such as diabetes mellitus, hyper-
ension, dyslipidemias, smoking, homocysteinemia (fast-
ng homocysteine 12 mol/l), or obesity. Based on
hese criteria, 14 patients were excluded because of the
resence of hypertension and 13 because of the presence
f other classic risk factors for atherosclerosis, such as
yslipidemia (n  6), smoking (n  9), diabetes mellitus
n  1), or a combination of more than 1 risk factor.
uring the treatment period, all patients were monitored
or side effects of ramipril treatment (such as cough, allergic
eactions, hypotension, or liver enzyme elevations), but none
f the participants required reduction or termination of the
rug use for any of these symptoms.tudy protocol. At baseline,
auge-strain plethysmography
as performed in the right fore-
rm and blood samples were ob-
ained. By the end of the first
isit, patients were randomized
o receive ramipril 5 mg/day or
o treatment (control) for 4
eeks in a randomized cross-
ver controlled trial, with 4
eeks’ wash-out period between
he 2 intervention periods (Fig.
). Gauge-strain plethysmogra-
hy was performed and blood
amples obtained at every visit.
n a pilot study, we established
hat the 4 weeks’ wash-out pe-
iod was adequate to allow for all the measured parameters
o return to their baseline levels.
There were no drop-outs during the study period. The
atients’ compliance to the treatment was monitored by
ounting the remaining treatment tablets at every visit.
he protocol of the study was approved by the Institu-
ional Ethics Committee of Hippokration Hospital, and
nformed consent was given by each subject.
orearm blood flow (FBF) measurements. We evaluated
ost-ischemic hyperemia as an index of endothelial func-
ion in the right forearm. It was previously shown that
O is responsible for 50% of hyperemic flow, and
eactive hyperemia (RH) is widely used as an index of
ndothelial function in human forearm circulation (12).
riefly, all measurements were performed in the morning
n a dark quiet room under constant temperature of 22°C
o 25°C. All subjects abstained from alcohol for 24 h and
Figure 1 Design of the Study
SCR  successful repair of coarctation of the aorta.
Abbreviations
and Acronyms
ACEI  angiotensin-
converting enzyme
inhibitor(s)
FBF  forearm blood blow
IL  interleukin
NO  nitric oxide
RH  reactive hyperemia
sCD40L  soluble CD40
ligand
SCR  successful repair of
coarctation of the aorta
sVCAM  soluble vascular
cell adhesion molecule
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Ramipril and Aortic Coarctation February 19, 2008:742–9rom food, tobacco, and caffeine-containing drinks for at
east 12 h before each vascular study. Before measure-
ents were started, subjects were rested in a supine
osition for 30 min. Forearm blood flow was measured
sing venous occlusion gauge-strain plethysmography
EC-400, D. E. Hokanson, Bellevue, Washington) as
reviously described (12). The FBF was calculated as the
ercentage change of arm volume per 100 ml tissue per
inute. Forearm vasodilatory response to RH was de-
ned as the percentage change of FBF from baseline to
he maximum FBF during reactive hyperemia after a
.5-min ischemic occlusion of the forearm. Ischemia of
he forearm was achieved by using an ischemic cuff at a
ressure 50 mm Hg higher than the patient’s systolic
lood pressure.
Forearm vasodilatory response to nitrate was defined as the
ercentage change of FBF from baseline to the maximum FBF
chieved after sublingual administration of nitroglycerin
NTG) 0.4 mg (12). The RH is considered to be a marker of
O bioavailability (because infusion of endothelial NO syn-
hase inhibitor NG-monomethyl-L-arginine inhibits RH by
50%) (12). Mean intra- and interobserver variabilities of RH
easurements in our laboratory in 20 healthy volunteers were
.1  1.7% and 4.1  1.9%, respectively.
iochemical determinations. Venous blood samples were
aken at the beginning of each protocol. After centrifugation
t 3,500 rpm at 4°C for 10 min, plasma or serum was
ollected and stored at 80°C until assayed. High-
ensitivity C-reactive protein (CRP) was measured by
article-enhanced immunonephelometry (N Latex, Dade-
ehring Marburg, Marburg, Germany). Serum levels of
nterleukin (IL)-1b, IL-6, and soluble vascular cell adhesion
olecule (sVCAM)-1 were determined by enzyme-linked
mmunosorbent assay (ELISA) (R&D Systems, Wiesbaden-
ordenstadt, Germany). Serum soluble CD40 ligand
sCD40L) was also determined by ELISA (Bender Med-
ystems, Vienna, Austria).
tatistical analysis. All variables were tested for normal
istribution using the Kolmokorov-Smirnov test. Normally
istributed variables are expressed as mean  SEM, and
RP (which was non-normally distributed) was log trans-
ormed for analysis and is presented in a nonlogarithmic
ormat as median (25th to 75th percentile). At the begin-
ing of the treatment, all variables were compared between
he 2 groups by using an unpaired t test. The effect of
reatment on each variable was examined by using 2-way
nalysis of variance (ANOVA). To test for order effects,
e also used an additional between-groups factor
ramipril first vs. control first groups), and we used
NOVA with 3 factors (to determine the group order 
reatment  time interactions). Correlations between
ariables were performed by univariate analysis, and the
earson r coefficient was estimated. All analyses were
arried out by using the SPSS version 12.0 statistical
ackage (SPSS Inc., Chicago, Illinois). desults
he demographic characteristics of the participants are
resented in Table 1. All patients complied with therapy,
nd there were no drop-outs. There were no significant
ifferences in any of the baseline/demographic characteris-
ics between the 2 groups. Treatment with ramipril signif-
cantly improved maximum hyperemic FBF (p  0.001)
nd RH (p  0.001) and had no effect on resting FBF (p 
S) or NTG (Table 2, Fig. 2). Although ramipril slightly
ecreased systolic blood pressure (Table 2), this decrease
as not associated with the changes in maximum hyperemic
BF (r  0.107; p  0.510) or RH (r  0.276; p 
.085). On the other hand, ramipril had no significant effect
n diastolic blood pressure (Table 2), and there was no
hange in systolic or diastolic blood pressures during the
ontrol period (Table 2). The improvements of maximum
yperemic FBF and RH induced by ramipril were signifi-
antly higher compared with the variations observed during
he control period (p  0.01) (Table 2). In addition, when
he change in systolic blood pressure was included as a
ovariate in the ANOVA analyses, there was no change in
he effect of treatment on maximum hyperemic FBF or RH.
To test whether ramipril treatment has any effect on the
xpression of proatherogenic inflammatory molecules, we
xamined the effect of treatment on proinflammatory cyto-
ines IL-1b and IL-6. Serum levels of IL-6 were signifi-
antly decreased after treatment with ramipril (p  0.05),
nd the decrease of IL-1b did not reach statistical signifi-
ance (p  0.055) (Table 2, Fig. 3). Similarly, serum
CD40L levels were significantly decreased after ramipril
reatment (p  0.01) (Table 2, Fig. 3), suggesting that
amipril may exert a general anti-inflammatory effect in
CR subjects.
Because proinflammatory cytokines stimulate the ex-
ression of adhesion molecules in vascular endothelium
nd the synthesis of acute-phase proteins in the liver, we
xamined whether ramipril thus had any effect on serum
evels of sVCAM-1 and CRP. Serum sVCAM-1 was
ignificantly decreased after ramipril treatment (p  0.01)
Table 2, Fig. 4). However, despite the trend toward a
opulation Characteristics
Table 1 Population Characteristics
SCR Patients
Subjects screened, n 50
Ssubjects excluded, n 27
Subjects who agreed to participate in the study, n 20
Gender (male/female) 13/7
Age (yrs) 27.3 2.4
Years after operation 13.9 2.2
Body mass index (kg/m2) 25.2 0.7
Systolic blood pressure (mm Hg) 121 3
Diastolic blood pressure (mm Hg) 72 2
alues expressed as mean  SEM.
SCR  successful repair of coarctation of aorta.ecrease of CRP levels after 4 weeks of treatment with
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February 19, 2008:742–9 Ramipril and Aortic Coarctationamipril, this change did not reach statistical significance
Table 2, Fig. 4). The decreases of IL-1b, IL-6, sCD40L,
nd sVCAM-1 induced by ramipril were significantly
reater compared with the respective variations observed
uring the control period (Table 2). When the change in
ystolic blood pressure was included as a covariate in the
NOVA analyses, it had no impact on the detected
ffects of Ramipril Treatment on Endothelial Function and Inflammroce s in Pat ents With Successfully R p ired Coarctation of the
Table 2 Effects of Ramipril Treatment on Endothelial FunctionProcess in Patients With Successfully Repaired Coarct
B
Con
Systolic blood pressure (mm Hg)† 12
Diastolic blood pressure (mm Hg) 7
Baseline FBF-1 (ml/100 ml tissue/min)
Maximum hyperemic FBF (ml/100 ml tissue/min)†
RH (%)† 4
Baseline FBF-2 (ml/100 ml tissue/min)
Maximum FBF after nitroglycerine administration (ml/100 ml tissue/min) 1
NTG (%) 7
C-reactive protein (mg/l) 1.03
Interleukin-6 (pg/ml)§ 1
Interleukin-1b (pg/ml)§ 0
sVCAM-1 (ng/ml)§ 50
sCD40L (ng/ml)§ 2
alues are expressed as mean  SEM or median (25th to 75th percentile). *Baseline or after 4 we
0.01 between the changes induced by the 2 interventions (control vs. placebo), as evaluated b
FBF forearm blood flow; NTG forearm vasodilatory response to sublingual nitroglycerin (0.4 m
oluble vascular cell adhesion molecule.
Figure 2 Effects of Ramipril on Forearm Hyperemic Responses
Treatment with ramipril had no effect on resting forearm blood flow (FBF) (A), whe
Ramipril had no effect on nitrate-induced vasodilation in the forearm (D to F). *pffects of treatment on each one of the examined inflam-
atory markers. Finally, there was no order effect on the
hange of any of the variables examined.
iscussion
mpaired endothelial function and an increased inflamma-
ory process are observed in subjects with SCR many years
nflammatory
of the Aorta
Control Ramipril 5 mg/day
e for
eriod*
After 4 Weeks
of No Treatment
Baseline for
Treatment Period*
After 4 Weeks of
Ramipril Treatment
3.7 121.7 3.6 121.0 3.9 110.3 2.5‡
2.5 72.5 3.9 72.8 2.5 71.3 2.3
0.4 5.6 0.4 5.5 0.3 5.5 0.4
0.5 7.8 0.7 7.4 0.4 8.9 0.5‡
5.4 41.4 5.4 37.3 4.7 62.3 6.3‡
0.5 6.4 0.6 6.1 0.5 6.0 0.6
1.0 10.8 0.9 11.0 1.0 10.8 1.1
5.8 70.4 5.2 71.7 6.8 71.6 4.9
–1.67) 1.02 (0.63–3.46) 0.90 (0.42–3.36) 0.60 (0.30–1.72)
0.18 1.34 0.18 1.80 0.29 0.88 0.11‡
0.28 0.95 0.27 0.83 0.27 0.26 0.02
43.3 504.6 33.5 646.9 65.8 445.7 39.4‡
0.35 2.47 0.38 2.83 0.50 1.44 0.19‡
shout, according to the randomization order. p  0.1; ‡p  0.05 versus baseline; §p  0.05; †p
analysis of variance.
 forearm vasodilatory response to reactive hyperemia; sCD40L soluble CD40 ligand; sVCAM
significantly improved maximum hyperemic FBF (B) and reactive hyperemia (C).
versus before treatment. NTG  forearm vasodilator response to nitrate.atoryA ta
and I
ation
aselin
trol P
0.0
4.0
5.5
7.7
3.5
6.2
1.1
8.0
(0.45
.28
.89
0.3
.07
eks’ wa
y 2-wayreas it
 0.01
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Ramipril and Aortic Coarctation February 19, 2008:742–9fter the operation and may have a strong effect on cardio-
ascular risk in these subjects. We examined whether
amipril treatment affects endothelial function and inflam-
atory process in normotensive subjects with SCR. We
emonstrated for the first time that 4 weeks of ramipril
reatment improves endothelial function and decreases the
xpression of IL-6, sCD40L, and sVCAM-1 in these
ubjects. These findings suggest that inhibition of ACE
Figure 3 Effects of Ramipril on sCD40L, IL-1b, and IL-6
Treatment with ramipril induced a borderline (p  0.055) decrease of interleukin (
CD40 ligand (sCD40L) (C) in normotensive subjects with successfully repaired coa
Figure 4 Effect of Ramipril on sVCAM-1 and CRP Levels
Treatment with ramipril induced a significant decrease of circulating soluble
vascular cell adhesion molecule (sVCAM)-1 (A). However, serum levels of
C-reactive protein (CRP) remained unchanged after 4 weeks’ treatment with
ramipril (B). *p  0.01 versus before treatment.May have direct antiatherogenic effects in subjects with
CR, even in the absence of arterial hypertension.
ffects of ramipril on endothelial function in subjects
ith SCR. It is widely believed that residual narrowing
t the site of surgery (especially during exercise) after
CR is partly responsible for the relapse of hypertension
n these subjects (13). However, the role of the aortic arc
eometry (classified as normal, Gothic, and Crenel) does
ot seem to be related to the development of exercise-
nduced hypertension in these subjects (14). On the other
and, the very first reports about the impact of vasore-
ctivity on the development of post-SCR hypertension
uggested that SCR patients with persisting post-
perative hypertension had greater vasoreactivity in re-
ponse to norepinephrine compared with those with
ormal blood pressure (15). It is now generally thought
hat endothelial dysfunction and decreased vascular NO
ioavailability are key mechanisms affecting forearm va-
oreactivity in SCR patients (2). In addition, evidence
uggests that noninvasive evaluation of endothelial func-
ion has a prognostic value in hypertensive individuals
16) and, most importantly, in subjects with SCR (2).
Evidence suggests that endothelial function in the pre-
oarctation arterial tree remains impaired many years after
CR (4). This could be the result of the relapsed arterial
ypertension often observed after SCR (1,8,17). Indeed,
ncreased post-operative levels of renin (18), reflecting the
ctivation of the renin-angiotensin system, have been ob-
erved in these patients even before the development of
rterial hypertension (19). This could be one of the mech-
nisms leading to the relapse of hypertension years after
CR, and may be directly implicated in the development
f endothelial dysfunction in these subjects, because
ngiotensin II suppresses NO production, generates toxic
ascular pro-oxidants, and enhances the production of
ndothelin-1 (a potent systemic vasoconstrictor) (20).
(A) and a significant decrease of IL-6 (B) and soluble
n of the aorta. *p  0.05; **p  0.01 versus before treatment.IL)-1b
rctatiooreover, endothelial dysfunction is not strictly dependent
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February 19, 2008:742–9 Ramipril and Aortic Coarctationn the existence of hypertension (4,5), because it persists
fter successful surgical repair even when blood pressure is
ormalized (21). On the other hand, structural changes on
he vascular wall, such as intimal and medial thickening,
isruption of the internal elastic lamina, and an increase in
he number of smooth muscle cells in the media (22), may
ontribute to the increased cardiovascular risk observed in
ubjects with SCR. The hypothesis that hypertension is not
he main cause (or may even be a result) of these vascular
bnormalities was also supported by our previous obser-
ations indicating that increased arterial stiffness is ob-
erved only in the pre-coarctation arterial tree (but not in
he post-coarctation vasculature) many years after SCR in
ormotensive subjects (4).
In addition to the effect of angiotensin II on endothelial
unction, there is evidence suggesting that it acts via angioten-
in type 1 receptors to alter sympathovagal balance during the
stablishment of coarctation hypertension, facilitating the sym-
athetic outflow to heart and peripheral circulation during
aroreceptor unloading (23). The role of the sympathetic
ystem in the development of post-SCR hyperdynamic circu-
ation and increase in systolic blood pressure has been docu-
ented by demonstrating a favorable effect of nonselective
eta-blockade by propranolol on the development of these
omplications (24). However, at a clinical level, beta-blockers
ay even induce a short-term increase of diastolic blood
ressure after SCR (25), and their usefulness is not widely
ccepted, because their effect on long-term outcome of these
atients has not been documented.
In the present study, we hypothesized that suppression of
he renin-angiotensin system by using the ACEI ramipril
ay improve endothelial function in SCR subjects. We
ound that ramipril leads to a significant improvement of
ndothelial function in the right forearm of subjects with
CR. This improvement of NO bioavailability may be
hrough both the direct induction of endothelial NO
roduction and the decreased breakdown of bradykinin,
hich indirectly induces the B2-receptor–mediated release
f endothelial NO (26).
ffects of ramipril on the inflammatory process. It is
idely accepted that inflammation is a key component of
therogenesis (27). Proinflammatory cytokines such as
L-1b and IL-6 trigger the synthesis of acute-phase proteins
such as CRP) in the liver and stimulate the expression of
dhesion molecules (such as VCAM-1), all with a major
redictive role in atherogenesis (27). Proinflamatory cyto-
ines are produced by a variety of tissues, including the
ascular wall (27), and serum levels of inflammatory medi-
tors are elevated in subjects with SCR in the absence of
ypertension or overt atherosclerosis (4). It is therefore
ikely that increased inflammatory molecules produced by
he dysfunctional arterial wall in the pre-coarctation arterial
ree, could lead to the development of premature athero-
clerosis (27), and it could also participate in the late pevelopment of arterial hypertension in subjects with
CR (28).
The observed activation of the renin-angiotensin system in
CR seems to promote the expression of inflammatory cyto-
ines, leading to further leukocyte activation in the systemic
irculation (29), which results in the direct elevation of
roatherogenic inflammatory load in these subjects (4). There
s strong evidence suggesting that inhibition of the renin-
ngiotensin system by ACEI (such as ramipril) depresses the
xpression of these proatherogenic inflammatory molecules in
his population, as observed with patients with coronary artery
isease (30), hypertension (31) or other risk factors for athero-
clerosis (32). This is thought to be via the reduction of
irculating angiotensin II levels. Angiotensin II up-regulates
he expression of inflammatory mediators controlled by redox-
ensitive pathways such as the nuclear factor kappa B pathway
nd others (26). This effect is thought to be via the activation
f angiotensin type 1 receptor, as was recently shown in
xperimental models (33). The second alternative pathway by
hich ACEI could reduce inflammatory stimulation is be-
ieved to be the reduction of blood pressure per se (34).
In the present study, we have shown that 4 weeks of
reatment with ramipril induced a significant decrease of IL-6
nd a borderline reduction of IL-1b levels in normotensive
CR patients, independently of blood pressure lowering, sug-
esting that inhibition of the renin-angiotensin system may
ave a significant direct anti-inflammatory effect in these
ubjects.
We have also shown that ramipril treatment decreases
erum sCD40L, an important proinflammatory molecule
nvolved in atherogenesis (35), which is secreted by both
ctivated platelets and the immune system (35). Evidence
uggests that sCD40L release in severe inflammatory con-
itions may be regulated by proinflammatory stimuli and
specially by cytokines such as IL-6, whereas ligation of
D40 mediates an array of proinflammatory effects in
ubjects with risk factors for atherosclerosis, including the
xpression of cytokines, chemokines, and adhesion mole-
ules (35). There is evidence that the sCD40L level is a
trong predictor of cardiovascular risk (36), but its role in
ubjects with SCR has not been evaluated until now. We
ave demonstrated that ramipril decreases sCD40L levels in
CR patients, suggesting that it may have a beneficial effect
n atherogenesis in this population.
A key mechanism by which proinflammatory cytokines
ffect atherogenesis is the up-regulation of the expression of
dhesion molecules on the endothelial surface, molecules
ith a critical role in platelet adhesion and migration to the
ubendothelial space (27). The soluble forms of adhesion
olecules such as sVCAM-1 seem to have a predictive value
n cardiovascular risk assessment (35). As we have previously
hown (4), subjects with SCR appear to have elevated
VCAM-1, suggesting that this inflammatory marker may
e a rational target for treatment at the level of primary
revention in these subjects. We have demonstrated in the
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Ramipril and Aortic Coarctation February 19, 2008:742–9resent study that 4 weeks’ treatment with ramipril de-
reases circulating sVCAM-1 levels independently of blood
ressure lowering, implying that treatment with ACEI may
ave antiatherogenic effects even in normotensive subjects
ith SCR.
Acute-phase proteins such as CRP have a major
redictive value in cardiovascular risk assessment (27,35).
lthough proinflammatory cytokines are the main stimuli
or the expression of CRP in the liver, 4 weeks’ treatment
ith ramipril failed to induce any change in CRP levels,
espite the lowering of IL-6 and sVCAM-1. This finding
ould be a result of the relatively short treatment period,
nd it requires further evaluation by longer-term clinical
rials.
tudy limitations. A limitation of this study is the absence
f angiographic evaluation of the degree of anatomic ob-
truction in the subjects. Although our patients had echo-
ardiographic estimation of the transcoarctation site
25 mm Hg, we cannot preclude the presence of recoarc-
ation, because the echocardiographic estimation is not as
ccurate as magnetic or invasive angiography. In addition,
he present study uses a short-term treatment period (only 4
eeks) and it has “soft” end points, such as endothelial
unction and the levels of inflammatory markers. Although
ndothelial function and inflammatory markers have a
redictive value for cardiovascular risk in the general pop-
lation, their true role in the outcome of patients with SCR
s still unknown. Therefore, the results of the present study
an only be used as the basis for the design of other
arge-scale clinical trials using long-term ACEI treatment
f normotensive patients with SCR to demonstrate a
ossible effect on cardiovascular risk. Only when the out-
omes of such studies are available could we address the
uestion of whether all SCR patients should routinely
eceive ramipril. Finally, it is unclear whether the levels of
he examined inflammatory markers are abnormally elevated
n SCR subjects. Despite our previous observation that SCR
ubjects have significantly greater levels of inflammatory
arkers compared with age- and gender-matched controls
4), the “normal range” for most of these markers remains
nclear (37).
onclusions
e demonstrated that 4 weeks’ treatment with ramipril
eads to an improvement of endothelial function in normo-
ensive patients with SCR, independently of blood pressure
owering. Furthermore, ramipril reduces the expression of
roatherogenic inflammatory cytokines (such as IL-6), ad-
esion molecules (sVCAM-1), and sCD40L in this popu-
ation. Taken together, these findings suggest that the
lockade of the renin-angiotensin system may be a rational
herapeutic target even in normotensive subjects with SCR,
nd it may lead to a reduction of overall cardiovascular risk.eprint requests and correspondence: Prof. Dimitris Tousoulis,
irst Cardiology Department, Athens University Medical School,
ippokration Hospital, Vasilissis Sofias 114, Postal Code 153 44,
thens, Greece. E-mail: tousouli@med.uoa.gr.
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